Anti-IRF3 (phospho S396) antibody [EPR28686-189] - BSA and Azide free
- Recombinant
- RabMAb
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Knockout Tested Rabbit Recombinant Monoclonal IRF3 phospho S396 antibody. Carrier free. Suitable for Dot, WB and reacts with Synthetic peptide, Human samples.
View Alternative Names
Interferon regulatory factor 3, IRF-3, IRF3
- WB
Supplier Data
Western blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] - BSA and Azide free (AB320083)
This data was developed using ab320082, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
In Western blot, ab320082 was shown to bind specifically to IRF3. Target of interest was observed at 60 kDa in wild-type Hela cell lysates (lane 2) with no signal observed at this size in IRF3 knockout cell line (lane 4) (lane 4, knockout cell line ab255345 / knockout cell lysate ab263784).
Lysates were freshly made and used for Western blotting immediately to minimize protein degradation.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.
In Western blot, Anti-IRF3 antibody [EPR2418Y] (ab68481) staining at 1/1000 dilution.
All lanes:
Western blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] (<a href='/en-us/products/primary-antibodies/irf3-phospho-s396-antibody-epr28686-189-ab320082'>ab320082</a>) at 1/1000 dilution
Lane 1:
Untreated wild-typeHeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate (untreated membrane) at 60 µg
Lane 2:
Wild-type HeLa treated first with 80nM TPA for 24h, then change fresh medium, transfect 10ug/ml poly(dA:dT) for 2h whole cell lysate (untreated membrane) at 60 µg
Lane 3:
Untreated IRF3 knockout HeLa whole cell lysate (untreated membrane) at 60 µg
Lane 4:
IRF3 knockout HeLa treated first with 80nM TPA for 24h, then change fresh medium, transfect 10ug/ml poly(dA:dT) for 2h whole cell lysate (untreated membrane) at 60 µg
Lane 5:
Untreated wild-typeHeLa whole cell lysate (alkaline phosphatase treated membrane) at 60 µg
Lane 6:
Wild-type HeLa treated first with 80nM TPA for 24h, then change fresh medium, transfect 10ug/ml poly(dA:dT) for 2h whole cell lysate (alkaline phosphatase treated membrane) at 60 µg
Lane 7:
Untreated IRF3 knockout HeLa whole cell lysate (alkaline phosphatase treated membrane) at 60 µg
Lane 8:
IRF3 knockout HeLa treated first with 80nM TPA for 24h, then change fresh medium, transfect 10ug/ml poly(dA:dT) for 2h whole cell lysate (alkaline phosphatase treated membrane) at 60 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Observed band size: 60 kDa,36 kDa
false
Exposure time: 92s
- WB
Supplier Data
Western blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] - BSA and Azide free (AB320083)
This data was developed using ab320082, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
The identity of the bands between 25 kDa and 35 kDa are unknown.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.
In Western blot, Anti-IRF3 antibody [EPR2418Y] (ab68481) staining at 1/1000 dilution.
All lanes:
Western blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] (<a href='/en-us/products/primary-antibodies/irf3-phospho-s396-antibody-epr28686-189-ab320082'>ab320082</a>) at 1/1000 dilution
Lane 1:
Untreated THP-1 (human monocytic leukemia monocyte) whole cell lysate at 60 µg
Lane 2:
THP-1 treated first with 80nM TPA for 24h, then change fresh medium, transfect 10ug/ml poly(dA:dT) for 2h whole cell lysate at 60 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Observed band size: 60 kDa,36 kDa
false
Exposure time: 48s
- Dot
Supplier Data
Dot Blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] - BSA and Azide free (AB320083)
This data was developed using ab320082, the same antibody clone in a different buffer formulation.
Dot blot analysis of IRF3 (phospho S396) using ab320082 at 1 : 1000 (0.509 ug/ml) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1 : 100,000 dilution.
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
All lanes:
Dot Blot - Anti-IRF3 (phospho S396) antibody [EPR28686-189] (<a href='/en-us/products/primary-antibodies/irf3-phospho-s396-antibody-epr28686-189-ab320082'>ab320082</a>) at 1/1000 dilution
Lane 1:
Human IRF3 (phospho S396) peptide 1
Lane 2:
Human IRF3 (phospho S396) peptide 2
Lane 3:
Human IRF3 non-phospho peptide
Lane 4:
Human IRF3 (phospho S398) peptide
Secondary
All lanes:
Dot Blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
false
Exposure time: 180s
Related conjugates and formulations (1)
-
Anti-IRF3 (phospho S396) antibody [EPR28686-189]
Reactivity data
Product details
ab320083 is the carrier-free version of ab320082.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF3 participates in the regulation of type I interferon (IFN) response a fundamental antiviral defense mechanism. IRF3 when phosphorylated forms a complex with CBP/p300 which then translocates to the nucleus to drive the expression of IFN-stimulated genes. This action strengthens the innate immune response and boosts the body's ability to counteract viral infections. Its activity and regulation are significant for maintaining a balanced immune response without excessive inflammation.
Pathways
IRF3 is involved in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) signaling pathways both essential in pathogen recognition and response. Within these pathways IRF3 interacts with proteins such as MAVS and TBK1 to propagate immune signaling. The activation of IRF3 in these pathways results in the production of type I interferons and other cytokines orchestrating an effective antiviral response. These interactions highlight the protein's central role in mediating immune signaling cascades.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com